Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2012767 | 1.00 | ELANE (0.40) | ELANEPRTN3HTTPKMTHRB | |
| SCHEMBL2008911 | 0.87 | LMNA (0.39) | HTTKDM4EALDH1A1MAPTLMNA | |
| SCHEMBL2008909 | 0.87 | LMNA (0.39) | HTTKDM4EALDH1A1MAPTLMNA | |
| SCHEMBL5996997 | 0.86 | BTN3A1 (0.40) | ELANEPRTN3HTTPKMBTN3A1 | |
| SCHEMBL643837 | 0.86 | BTN3A1 (0.40) | ELANEPRTN3HTTPKMBTN3A1 | |
| SCHEMBL7771222 | 0.82 | PPARG (0.40) | ELANEPRTN3 | |
| SCHEMBL1810431 | 0.82 | ANPEP (0.45) | ELANEBTN3A1ANPEPLAP3 | |
| SCHEMBL10004179 | 0.81 | NPC1 (0.49) | ELANEPRTN3ALDH1A1 | |
| SCHEMBL10004866 | 0.81 | SMN1; SMN2 (0.41) | HTTKDM4EALDH1A1MMP9 | |
| SCHEMBL10004224 | 0.80 | SMN1; SMN2 (0.40) | HTTKDM4EALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12121529-B2 | Nucleoside phosphoramidate prodrugs | GILEAD SCIENCES, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| EP-2203462-B2 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD PHARMASSET LLC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240139227-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD PHARMASSET LLC | 2024-05-02 | — | — | US | disclosed |
| EP-4282482-A2 | Nucleoside phosphoramidate prodrugs | Gilead Sciences, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-2801580-B1 | Nucleoside phosphoramidate prodrugs | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11642361-B2 | Nucleoside phosphoramidate prodrugs | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210196741-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD PHARMASSET LLC | 2021-07-01 | — | — | US | disclosed |
| EP-2826784-B1 | Composition comprising a HCV NS3 protease inhibitor and a phosphoramidate prodrug of 2'-deoxy-2'-fluoro-2'-C-methyluridine nucleoside | GILEAD PHARMASSET LLC (US) | 2019-06-26 | — | — | EP | disclosed |
| US-10183037-B2 | Nucleoside phosphoramidate prodrugs | GILEAD PHARMASSET LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180000855-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD SCIENCES, INC. | 2018-01-04 | — | — | US | disclosed |
| US-8334270-B2 | Nucleoside phosphoramidate prodrugs | GILEAD PHARMASSET LLC (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110257122-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PHARMASSET, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7964580-B2 | Nucleoside phosphoramidate prodrugs | PHARMASSET, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2203462-A2 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | Pharmasset, Inc. (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20100016251-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PHARMASSET, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2008121634-A2 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PHARMASSET, INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| EP-1117669-B1 | ANTIVIRAL PURINE DERIVATIVES | UNIV CARDIFF (GB) | 2003-01-29 | — | — | EP | disclosed |
| US-20010031745-A1 | Antiviral purine derivatives | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2001-10-18 | — | — | US | disclosed |
| EP-1117669-A1 | ANTIVIRAL PURINE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD. (GB) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018775-A1 | ANTIVIRAL PURINE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139227-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | ELANE 841/4885PRTN3 485/4885HTT 3775/4885 |
| US-20100016251-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | ELANE 841/4885PRTN3 485/4885HTT 3775/4885 |
| US-11642361-B2 | Nucleoside phosphoramidate prodrugs | PNP, NUDT1, TYMP | ELANE 841/4885PRTN3 485/4885HTT 3775/4885 |
| US-20180000855-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | ELANE 841/4885PRTN3 485/4885HTT 3775/4885 |
| US-20110257122-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | ELANE 841/4885PRTN3 485/4885HTT 3775/4885 |
| US-20010031745-A1 | Antiviral purine derivatives | PNP, TYMP, MTAP | ELANE 3126/4885PRTN3 657/4885HTT 4152/4885 |
| US-20210196741-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PNP, NUDT1, TYMP | ELANE 841/4885PRTN3 485/4885HTT 3775/4885 |
| US-12121529-B2 | Nucleoside phosphoramidate prodrugs | PNP, NUDT1, TYMP | ELANE 841/4885PRTN3 485/4885HTT 3775/4885 |
| US-10183037-B2 | Nucleoside phosphoramidate prodrugs | PNP, NUDT1, TYMP | ELANE 841/4885PRTN3 485/4885HTT 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.